Epigenetic Targets: On the verge of becoming a major new category for successful drug research By Dr John Comley Most vendors of epigenetic modification proteins and reagents have enhanced and broadened their offerings in recent years. Of particular note is the increasing range of proteins and binding… Read More
BioPharma and CROs Collaborating In Early Drug Discovery By Dr John Montana and Cornelis E.C.A. Hop BioPharma and CROs are riding the latest wave – discovery research – together with a vigour and gusto that might have seemed implausible five years ago. How these collaborations are structured, and… Read More
Misconduct in the biomedical sciences part 2: detection and prevention By Dr Gerald H. Lushington and Rathnam Chaguturu Discovering safe and effective medicines, one of the greatest gifts to humanity, relies intensely upon the availability of detailed, unassailably accurate biomedical scientific knowledge. The… Read More
Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors By Dr Cenk Sumen, Dr Dan Williams and Dr Gwendolyn Binder-Scholl T-cells with engineered receptors to target tumours represent living drugs with enormous potential in the fight against cancer, but many challenges remain to be overcome in order… Read More
Precise genome editing: the key to a CRISPR drug discovery pipeline? By Dr. J. D. Wrigley, Dr M Maresca, Dr K Birmingham, Dr M Bohlooly-Y and Dr L M. Mayr From the pioneering days of Watson and Crick in 1953, to completion of the human genome project in… Read More
Misconduct in the biomedical sciences part 1: issues and causes By Dr Gerald H. Lushington and Rathnam Chaguturu Science pursues truth. Real advances in biomedical sciences improve our quality of life and save lives, but the path to these advances is cluttered with the distraction of irreproducible results… Read More
Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable. Read More
By Dr Andy Tsun, Jia Li, Joanne Sun, Dr Michael Yu, Dr Yajie Li and Xiaolin Liu In the past decade, China’s drug market has been expanding in double-digit percentages. This has brought about a huge increase in local drug makers and has lured multinational pharmaceutical… Read More
Restucturing Proteomics: The rise of next-generation affinity reagents By Dr Paul Ko Ferrigno & Dr Jane McLeod The ability of antibodies to bind their target proteins with some degree of specificity has elevated them to being among the most useful tools in biology and medicine, with a market… Read More
Opportunities For Phenotypic Screening In Drug Discovery By David C. Swinney Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers,… Read More
Industrial-Scale Screening Accelerates Discovery of Novel Drug Combination Therapies By Dr Oliver Leven and Dr Eric Tang Drug combination therapies are widely recognised as essential therapeutic treatments for chronic conditions ranging from infectious diseases to cancer and HIV/AIDS. Such therapies can enhance a clinical efficacy profile, improve the… Read More
Reconfiguring Drug Discovery Through Innovative Partnerships By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion… Read More
By Dr Scott R. Burger, Louis Juliano, and Dr Wenshi Wang For more than two decades, the biotechnology and pharmaceutical industries have been working to unlock the great potential of cell therapy, which uses products composed of living, functional cells to mediate the therapeutic effect. Read More
Oncology Target Discovery by RNAi: The past, present, and future perspectives By Dr Hakim Djaballah and Bhavneet Bhinder Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need… Read More
Automating The Drive Towards Personalised Medicine By Dr Alexandre Akoulitchev, Dr Howard Womersley and Dr Phil Jordan Interest in personalised medicine continues to grow, and epigenetic biomarkers are very informative in this respect, giving a clear indication of whether (and how) a patient’s gene expression profile has changed,… Read More
Library Logistics: Managing Comprehensive Compound Collections By Dr Jorg Kroll and David Booth Compound management may seem straightforward but in reality, as the number of new compounds increases dramatically year-on-year, the management of large collections has become increasingly challenging. A… Read More
